UBS Downgrades Chemours to Neutral, Lowers Price Target to $18

Benzinga Newsdesk www.benzinga.com Negative 88.8%

Neg 88.8% Neu 0% Pos 0%

UBS analyst Joshua Spector downgrades Chemours (NYSE:CC) from Buy to Neutral and lowers the price target from $29 to $18.